Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):270–277. doi: 10.1054/bjoc.1999.0914

Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women

M G Daidone 1, A Luisi 1, G Martelli 1, E Benini 1, S Veneroni 1, G Tomasic 1, G De Palo 1, R Silvestrini 1
PMCID: PMC2363285  PMID: 10646876

Abstract

The predictive role of tumour proliferative rate and expression of p53, bcl-2 and bax proteins, alone and in association with tumour size, nodal involvement and oestrogen receptors (ER), was analysed on 145 elderly patients (≥70 years of age) with histologically assessed node-positive breast cancers treated with radical or conservative surgery plus radiotherapy followed by adjuvant tamoxifen for at least 1 year. The 7-year probability of relapse was significantly higher for patients with tumours rapidly proliferating (hazard ratio (HR) = 2.0, P = 0.01), overexpressing p53 (HR = 4.4, P = 0.0001), weakly or not exhibiting bcl-2 (HR = 1.9, P = 0.02), without ERs (HR = 3.4, P = 0.0001) or with ≥ 4 positive lymph nodes (HR = 2.3, P = 0.003) than for patients with tumours expressing the opposite patho-biological profile. Conversely, tumour size and bax expression failed to influence relapse-free survival. Adjustment for the duration of tamoxifen treatment did not change these findings. Oestrogen receptors, cell proliferation, p53 accumulation and bcl-2 expression were also predictive for overall survival. Within ER-positive tumours, cell proliferation, p53 accumulation, bcl-2 expression and lymph node involvement provided significant and independent information for relapse and, in association, identified subgroups of patients with relapse probabilities of 20% (low-risk group, exhibiting only one unfavourable factor) to 90% (high-risk group, exhibiting three unfavourable factors). Such data could represent the initial framework for a biologically tailored therapy even for elderly patients and highlight the importance of a patho-biological characterization of their breast cancers. © 2000 Cancer Research Campaign

Keywords: bcl-2 expression, cell proliferation, elderly patients, hormone responsiveness, p53 expression, oestrogen receptors

Full Text

The Full Text of this article is available as a PDF (107.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Archer S. G., Eliopoulos A., Spandidos D., Barnes D., Ellis I. O., Blamey R. W., Nicholson R. I., Robertson J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995 Nov;72(5):1259–1266. doi: 10.1038/bjc.1995.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Balducci L., Extermann M., Fentiman I., Monfardini S., Perrone F. Should adjuvant chemotherapy be used to treat breast cancer in elderly patients (> or = 70 years of age)? Eur J Cancer. 1997 Oct;33(11):1720–1724. doi: 10.1016/s0959-8049(97)00297-9. [DOI] [PubMed] [Google Scholar]
  3. Berns E. M., Klijn J. G., van Putten W. L., de Witte H. H., Look M. P., Meijer-van Gelder M. E., Willman K., Portengen H., Benraad T. J., Foekens J. A. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. J Clin Oncol. 1998 Jan;16(1):121–127. doi: 10.1200/JCO.1998.16.1.121. [DOI] [PubMed] [Google Scholar]
  4. Carlomagno C., Perrone F., Gallo C., De Laurentiis M., Lauria R., Morabito A., Pettinato G., Panico L., D'Antonio A., Bianco A. R. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996 Oct;14(10):2702–2708. doi: 10.1200/JCO.1996.14.10.2702. [DOI] [PubMed] [Google Scholar]
  5. Clahsen P. C., van de Velde C. J., Duval C., Pallud C., Mandard A. M., Delobelle-Deroide A., van den Broek L., Sahmoud T. M., van de Vijver M. J. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol. 1998 Feb;16(2):470–479. doi: 10.1200/JCO.1998.16.2.470. [DOI] [PubMed] [Google Scholar]
  6. Costa A., Licitra L., Veneroni S., Daidone M. G., Grandi C., Cavina R., Molinari R., Silvestrini R. Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. Int J Cancer. 1998 Dec 18;79(6):619–623. doi: 10.1002/(sici)1097-0215(19981218)79:6<619::aid-ijc11>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  7. Di Fronzo G., Coradini D., Cappelletti V., Miodini P., Granata G., Schwartz M., Panko W. B. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels. Anticancer Res. 1990 Nov-Dec;10(6):1699–1705. [PubMed] [Google Scholar]
  8. Elledge R. M., Gray R., Mansour E., Yu Y., Clark G. M., Ravdin P., Osborne C. K., Gilchrist K., Davidson N. E., Robert N. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995 Aug 16;87(16):1254–1256. doi: 10.1093/jnci/87.16.1254. [DOI] [PubMed] [Google Scholar]
  9. Elledge R. M., Green S., Howes L., Clark G. M., Berardo M., Allred D. C., Pugh R., Ciocca D., Ravdin P., O'Sullivan J. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997 May;15(5):1916–1922. doi: 10.1200/JCO.1997.15.5.1916. [DOI] [PubMed] [Google Scholar]
  10. Elledge R. M., Lock-Lim S., Allred D. C., Hilsenbeck S. G., Cordner L. p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct;1(10):1203–1208. [PubMed] [Google Scholar]
  11. Frassoldati A., Adami F., Banzi C., Criscuolo M., Piccinini L., Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat. 1997 Jul;44(3):185–192. doi: 10.1023/a:1005875002458. [DOI] [PubMed] [Google Scholar]
  12. Gasparini G., Barbareschi M., Doglioni C., Palma P. D., Mauri F. A., Boracchi P., Bevilacqua P., Caffo O., Morelli L., Verderio P. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995 Feb;1(2):189–198. [PubMed] [Google Scholar]
  13. Gasparini G., Pozza F., Harris A. L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst. 1993 Aug 4;85(15):1206–1219. doi: 10.1093/jnci/85.15.1206. [DOI] [PubMed] [Google Scholar]
  14. Gee J. M., Robertson J. F., Ellis I. O., Willsher P., McClelland R. A., Hoyle H. B., Kyme S. R., Finlay P., Blamey R. W., Nicholson R. I. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994 Dec 1;59(5):619–628. doi: 10.1002/ijc.2910590508. [DOI] [PubMed] [Google Scholar]
  15. Hellemans P., van Dam P. A., Weyler J., van Oosterom A. T., Buytaert P., Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995 Aug;72(2):354–360. doi: 10.1038/bjc.1995.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hurlimann J., Larrinaga B., Vala D. L. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 1995;426(2):163–168. doi: 10.1007/BF00192638. [DOI] [PubMed] [Google Scholar]
  17. Jansson T., Inganäs M., Sjögren S., Norberg T., Lindgren A., Holmberg L., Bergh J. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol. 1995 Nov;13(11):2745–2751. doi: 10.1200/JCO.1995.13.11.2745. [DOI] [PubMed] [Google Scholar]
  18. Keen J. C., Dixon J. M., Miller E. P., Cameron D. A., Chetty U., Hanby A., Bellamy C., Miller W. R. The expression of Ki-S1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat. 1997 Jun;44(2):123–133. doi: 10.1023/a:1005796915388. [DOI] [PubMed] [Google Scholar]
  19. Kobayashi S., Iwase H., Ito Y., Yamashita H., Iwata H., Yamashita T., Ito K., Toyama T., Nakamura T., Masaoka A. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat. 1997 Jan;42(2):173–181. doi: 10.1023/a:1005760013810. [DOI] [PubMed] [Google Scholar]
  20. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V. M., Niskanen E., Nordling S., Reed J. C. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995 Oct 1;55(19):4471–4478. [PubMed] [Google Scholar]
  21. Krajewski S., Thor A. D., Edgerton S. M., Moore D. H., 2nd, Krajewska M., Reed J. C. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res. 1997 Feb;3(2):199–208. [PubMed] [Google Scholar]
  22. Martelli G., DePalo G., Rossi N., Coradini D., Boracchi P., Galante E., Vetrella G. Long-term follow-up of elderly patients with operable breast cancer treated with surgery without axillary dissection plus adjuvant tamoxifen. Br J Cancer. 1995 Nov;72(5):1251–1255. doi: 10.1038/bjc.1995.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Ravdin P. M., Clark G. M. Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer. 1992 Sep 15;70(6 Suppl):1775–1781. doi: 10.1002/1097-0142(19920915)70:4+<1775::aid-cncr2820701619>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  24. Nathan B., Gusterson B., Jadayel D., O'Hare M., Anbazhagan R., Jayatilake H., Ebbs S., Micklem K., Price K., Gelber R. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1994 May;5(5):409–414. doi: 10.1093/oxfordjournals.annonc.a058871. [DOI] [PubMed] [Google Scholar]
  25. Nicholson R. I., Bouzubar N., Walker K. J., McClelland R., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer. 1991;27(7):908–913. doi: 10.1016/0277-5379(91)90145-4. [DOI] [PubMed] [Google Scholar]
  26. Paik S., Bryant J., Park C., Fisher B., Tan-Chiu E., Hyams D., Fisher E. R., Lippman M. E., Wickerham D. L., Wolmark N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998 Sep 16;90(18):1361–1370. doi: 10.1093/jnci/90.18.1361. [DOI] [PubMed] [Google Scholar]
  27. Paradiso A., Tommasi S., Mangia A., Lorusso V., Simone G., De Lena M. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res. 1990 May 15;50(10):2958–2962. [PubMed] [Google Scholar]
  28. Piffanelli A., Pelizzola D., Giovannini G., Catozzi L., Faggioli L., Giganti M. Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization. Tumori. 1989 Dec 31;75(6):550–556. doi: 10.1177/030089168907500607. [DOI] [PubMed] [Google Scholar]
  29. Ronchi E., Granata G., Brivio M., Coradini D., Miodini P., Di Fronzo G. A double-labeling assay for simultaneous estimation and characterization of estrogen and progesterone receptors using radioiodinated estradiol and tritiated Org 2058. Tumori. 1986 Jun 30;72(3):251–257. doi: 10.1177/030089168607200305. [DOI] [PubMed] [Google Scholar]
  30. Silliman R. A., Balducci L., Goodwin J. S., Holmes F. F., Leventhal E. A. Breast cancer care in old age: what we know, don't know, and do. J Natl Cancer Inst. 1993 Feb 3;85(3):190–199. doi: 10.1093/jnci/85.3.190. [DOI] [PubMed] [Google Scholar]
  31. Silvestrini R., Benini E., Daidone M. G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993 Jun 16;85(12):965–970. doi: 10.1093/jnci/85.12.965. [DOI] [PubMed] [Google Scholar]
  32. Silvestrini R., Benini E., Veneroni S., Daidone M. G., Tomasic G., Squicciarini P., Salvadori B. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol. 1996 May;14(5):1604–1610. doi: 10.1200/JCO.1996.14.5.1604. [DOI] [PubMed] [Google Scholar]
  33. Silvestrini R., Daidone M. G., Luisi A., Boracchi P., Mezzetti M., Di Fronzo G., Andreola S., Salvadori B., Veronesi U. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol. 1995 Mar;13(3):697–704. doi: 10.1200/JCO.1995.13.3.697. [DOI] [PubMed] [Google Scholar]
  34. Silvestrini R., Daidone M. G., Mastore M., Di Fronzo G., Coradini D., Boracchi P., Squicciarini P., Salvadori B., Veronesi U. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol. 1993 Jun;11(6):1150–1155. doi: 10.1200/JCO.1993.11.6.1150. [DOI] [PubMed] [Google Scholar]
  35. Silvestrini R. Feasibility and reproducibility of the [3H]-thymidine labelling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic Determination. Cell Prolif. 1991 Sep;24(5):437–445. doi: 10.1111/j.1365-2184.1991.tb01172.x. [DOI] [PubMed] [Google Scholar]
  36. Silvestrini R., Rao S., Benini E., Daidone M. G., Pilotti S. Immunohistochemical detection of p53 in clinical breast cancers: a look at methodologic approaches. J Natl Cancer Inst. 1995 Jul 5;87(13):1020–1020. doi: 10.1093/jnci/87.13.1020. [DOI] [PubMed] [Google Scholar]
  37. Silvestrini R., Veneroni S., Benini E., Daidone M. G., Luisi A., Leutner M., Maucione A., Kenda R., Zucali R., Veronesi U. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst. 1997 May 7;89(9):639–645. doi: 10.1093/jnci/89.9.639. [DOI] [PubMed] [Google Scholar]
  38. Silvestrini R., Veneroni S., Daidone M. G., Benini E., Boracchi P., Mezzetti M., Di Fronzo G., Rilke F., Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994 Apr 6;86(7):499–504. doi: 10.1093/jnci/86.7.499. [DOI] [PubMed] [Google Scholar]
  39. Sjögren S., Inganäs M., Lindgren A., Holmberg L., Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998 Feb;16(2):462–469. doi: 10.1200/JCO.1998.16.2.462. [DOI] [PubMed] [Google Scholar]
  40. Stål O., Skoog L., Rutqvist L. E., Carstensen J. M., Wingren S., Sullivan S., Andersson A. C., Dufmats M., Nordenskjöld B. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer. 1994 Dec;70(6):1258–1262. doi: 10.1038/bjc.1994.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Thor A. D., Berry D. A., Budman D. R., Muss H. B., Kute T., Henderson I. C., Barcos M., Cirrincione C., Edgerton S., Allred C. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16;90(18):1346–1360. doi: 10.1093/jnci/90.18.1346. [DOI] [PubMed] [Google Scholar]
  42. Valentinis B., Silvestrini R., Daidone M. G., Coradini D., Galante E., Cerrotta A. M., Abolafio G., Arboit L. 3H-thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients. Breast Cancer Res Treat. 1991 Dec;20(1):19–24. doi: 10.1007/BF01833353. [DOI] [PubMed] [Google Scholar]
  43. Veronese S., Mauri F. A., Caffo O., Scaioli M., Aldovini D., Perrone G., Galligioni E., Doglioni C., Dalla Palma P., Barbareschi M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer. 1998 Feb 20;79(1):13–18. doi: 10.1002/(sici)1097-0215(19980220)79:1<13::aid-ijc3>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  44. Veronesi U., Saccozzi R., Del Vecchio M., Banfi A., Clemente C., De Lena M., Gallus G., Greco M., Luini A., Marubini E. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981 Jul 2;305(1):6–11. doi: 10.1056/NEJM198107023050102. [DOI] [PubMed] [Google Scholar]
  45. van Slooten H. J., Clahsen P. C., van Dierendonck J. H., Duval C., Pallud C., Mandard A. M., Delobelle-Deroide A., van de Velde C. J., van de Vijver M. J. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996 Jul;74(1):78–85. doi: 10.1038/bjc.1996.319. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES